 |
 |

Early Ibuprofen Administration to Prevent Patent Ductus Arteriosus in Premature Newborn Infants
Anastasia Varvarigou, MD;
Claudette L. Bardin, MD, PhD;
Kay Beharry;
Sylvain Chemtob, MD, PhD, FRCPC;
Apostolos Papageorgiou, MD, FRCPC;
Jacob V. Aranda, MD, PhD, FRCPC
JAMA. 1996;275(7):539-544.
Abstract
 |  |
Objective. —To test whether early postnatal (0 to 3 hours) intravenous administration of ibuprofen will prevent patent ductus arteriosus (PDA) in preterm neonates.
Design. —Prospective sequential controlled trial with three treatment arms.
Setting. —Level 3 perinatal-neonatal intensive care nursery.
Patients. —Thirty-four premature newborn infants born from February to August 1993 with a mean birth weight of 913 g (range, 565 to 1460 g) and gestational age of 26.9 weeks (range, 22.4 to 31.0).
Intervention. —Infants were consecutively assigned within 3 hours of age to treatment with either one dose of ibuprofen lysine (10 mg/kg intravenously) followed by 5 mg/kg per dose intravenously at 24 and 48 hours of age (n=12), one dose of ibuprofen Iysine (10 mg/kg intravenously; n=11), or saline (n=11).
Outcome Variables. —Primary outcome variable was the presence of ductus arteriosus by echocardiography and clinical assessments at 3, 7, and 21 days of life. Secondary outcome variables included presence of intraventricular hemorrhage, renal function, ventilatory and oxygen needs, hematologic changes, gastrointestinal function, time to full enteral feeding, duration of hospitalization, and age at discharge.
Results. —The three groups of patients were comparable in birth weight, gestational age, antenatal administration of betamethasone, and other perinatal characteristics. Ibuprofen treatment significantly reduced plasma levels of prostaglandins, and the levels remained low for 72 hours in newborns who received three doses of the drug. The incidence of PDA and other variables did not differ between patients who received a single dose of ibuprofen and those given saline. However, compared with the saline-treated newborns, babies who received three doses of ibuprofen had no PDA (0/12 vs 7/11 for saline; P<.02), had lower daily mean airway pressures (mean±SD, 5.2±1.1 cm H2O vs 8.3±2.8cm H2O for saline; P<.02) and better oxygenation index (2.6±0.6 vs 4.7±1.8 for saline; P<.02) at the end of the first week of life, and required fewer days of ventilation (25±14 days vs 44±26 days for saline; P<.03). Babies given three doses of ibuprofen tended to tolerate full oral feedings earlier (35±19 days vs 56±34 days for saline; P=.09), had shorter duration of hospitalization (71.2±22.6 days vs 127.3±74.7 days for saline; P<.05), and were discharged to home at an earlier postconceptional age (37.8±2.0 weeks vs 44.8±9.8 weeks for saline; P<.05). Ibuprofen treatment in this phase I trial was not associated with any apparent early neurological, intestinal, renal, hepatic, or hematologic complications.
Conclusions. —Administration of three doses of ibuprofen within 3 hours after birth in preterm neonates reduced the incidence of PDA without causing notable early adverse drug reactions in this phase I trial. Early closure of the ductus arteriosus was also associated with better respiratory outcome and earlier discharge from the hospital.
(JAMA. 1996;275:539-544)
Author Affiliations
From the Department of Neonatology and the Centre for Perinatal and Developmental Pharmacology Research, Lady Davis Institute—SMBD Jewish General Hospital, Departments of Pediatrics, and Pharmacology and Therapeutics, McGill University, Montreal, Quebec (Drs Varvarigou, Bardin, Papageorgiou, and Aranda and Ms Beharry), and Departments of Pediatrics and Pharmacology, University of Montreal (Dr Chemtob). Dr Varvarigou is now with the Department of Pediatrics, University of Patras (Greece).
Footnotes
Reprint requests to McGill University, Lady Davis Institute for Medical Research, 3755 Côte St-Catherine Rd, Montreal, Quebec, Canada H3T 1E2 (Dr Aranda).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Randomized Pilot Study Comparing Oral Ibuprofen With Intravenous Ibuprofen in Very Low Birth Weight Infants With Patent Ductus Arteriosus
Cherif et al.
Pediatrics 2008;122:e1256-e1261.
ABSTRACT
| FULL TEXT
Population Pharmacokinetic Analysis of Ibuprofen Enantiomers in Preterm Newborn Infants
Gregoire et al.
J Clin Pharmacol 2008;48:1460-1468.
ABSTRACT
| FULL TEXT
Comparison of ibuprofen and indometacin for early-targeted treatment of patent ductus arteriosus in extremely premature infants: a randomised controlled trial
Su et al.
Arch. Dis. Child. Fetal Neonatal Ed. 2008;93:F94-F99.
ABSTRACT
| FULL TEXT
Conservative treatment for patent ductus arteriosus in the preterm
Vanhaesebrouck et al.
Arch. Dis. Child. Fetal Neonatal Ed. 2007;92:F244-F247.
ABSTRACT
| FULL TEXT
Comparative Effects of Early Postnatal Ibuprofen and Indomethacin on VEGF, IGF-I, and GH during Rat Ocular Development.
Beharry et al.
IOVS 2006;47:3036-3043.
ABSTRACT
| FULL TEXT
Recent Advances in Neonatal Pharmacotherapy
Calhoun et al.
The Annals of Pharmacotherapy 2006;40:710-719.
ABSTRACT
| FULL TEXT
Pharmacology Review: Intravenous Ibuprofen for Preterm Newborns
Aranda and Thomas
NeoReviews 2005;6:e516-e523.
FULL TEXT
Prophylactic Ibuprofen for the Prevention of Intraventricular Hemorrhage Among Preterm Infants: A Multicenter, Randomized Study
Dani et al.
Pediatrics 2005;115:1529-1535.
ABSTRACT
| FULL TEXT
Population Pharmacokinetics of Ibuprofen Enantiomers in Very Premature Neonates
Gregoire et al.
J Clin Pharmacol 2004;44:1114-1124.
ABSTRACT
| FULL TEXT
Prophylactic nasal continuous positive airways pressure in newborns of 28-31 weeks gestation: multicentre randomised controlled clinical trial
Sandri et al.
Arch. Dis. Child. Fetal Neonatal Ed. 2004;89:F394-F398.
ABSTRACT
| FULL TEXT
Closure of Patent Ductus Arteriosus With Oral Ibuprofen Suspension in Premature Newborns: A Pilot Study
Heyman et al.
Pediatrics 2003;112:e354-354.
ABSTRACT
| FULL TEXT
Effect of early targeted indomethacin on the ductus arteriosus and blood flow to the upper body and brain in the preterm infant
Osborn et al.
Arch. Dis. Child. Fetal Neonatal Ed. 2003;88:F477-482.
ABSTRACT
| FULL TEXT
Pharmacokinetics of Oral Ibuprofen in Premature Infants
Sharma et al.
J Clin Pharmacol 2003;43:968-973.
ABSTRACT
| FULL TEXT
Pharmacology Review: Pharmacologic Closure of Patent Ductus Arteriosus in the Neonate
Narayanan-Sankar and Clyman
NeoReviews 2003;4:e215-221.
FULL TEXT
A Comparison of Ibuprofen and Indomethacin for Closure of Patent Ductus Arteriosus
Overmeire et al.
NEJM 2000;343:674-681.
ABSTRACT
| FULL TEXT
Ibuprofen and Patent Ductus Arteriosus
Clyman
NEJM 2000;343:728-730.
FULL TEXT
Treatment of patent ductus arteriosus with ibuprofen
Van Overmeire et al.
Arch. Dis. Child. Fetal Neonatal Ed. 1997;76:179F-184.
ABSTRACT
| FULL TEXT
IBUPROFEN MAY PREVENT PATENT DUCTUS ARTERIOSUS IN NEONATES
JWatch General 1996;1996:5-5.
FULL TEXT
|